BHCM
XERS icon

Brevan Howard Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Brevan Howard Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.4K Sell
15,753
-76,663
-83% -$508K ﹤0.01% 2043
2025
Q4 		$725K Sell
92,416
-39,744
-30% -$313K 0.01% 916
2025
Q3 		$1.08M Sell
132,160
-72,864
-36% -$484K ﹤0.01% 866
2025
Q2 		$957K Buy
205,024
+12,748
+7% +$58.4K 0.01% 1083
2025
Q1 		$1.06M Buy
+192,276
New +$776K 0.01% 479

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brevan Howard Capital Management's XERS Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Xeris Biopharma Holdings (XERS) stake by 83% in Q1 2026, selling an estimated $508K and leaving 15,753 shares worth $91.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Brevan Howard Capital Management first reported a position in XERS in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.08M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Brevan Howard Capital Management held 15,753 shares of Xeris Biopharma Holdings worth $91.4K as of Q1 2026.
  • Brevan Howard Capital Management sold 76,663 Xeris Biopharma Holdings shares in Q1 2026, an estimated $508K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2043 holding.
  • Brevan Howard Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2025 and has held it in 5 quarters since.
  • Brevan Howard Capital Management's Xeris Biopharma Holdings position peaked at $1.08M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.